Manufacturing, Research and Development
June 14, 2022
Via: Biopharma DiveAlnylam, a pioneer in the drugmaking method known as RNA interference, has climbed the biotech industry ranks over the last two decades. After solving challenges associated with delivering these treatments into the body, Alnylam has become one of the sector’s […]
Manufacturing, Research and Development
June 9, 2022
Via: Biopharma DiveWhile recent years have seen scientists make major advances in cutting-edge treatments such as gene and cell therapies, manufacturing remains a significant hurdle. The complex, multi-step processes required are beyond the capabilities of a traditional pharmaceutical plant. That’s where Resilience […]
Cell and Gene Therapy, Industry, Manufacturing, Research and Development
June 9, 2022
Via: Contract PharmaRegenxbio recently celebrated the opening of its new Manufacturing Innovation Center gene therapy manufacturing facility. “Launching operations at our Manufacturing Innovation Center is an important milestone in the evolution of REGENXBIO,” said Kenneth T. Mills, president and CEO of REGENXBIO. […]
June 6, 2022
Via: Biopharma DiveAfter nearly eight years, Yumanity’s time as an independent company appears close to an end. The biotech was established in late 2014 — the creation of Tony Coles, Susan Lindquist and Ken Rhodes, each well-known in the pharmaceutical industry for […]
June 2, 2022
Via: Biopharma DiveThe most immediate effect of the deal is a much-needed infusion of funds for Repare, which went public in 2020 at a price of $20 a share. The company’s stock soared above $42 in early 2021, only to plummet as […]
May 31, 2022
Via: Biopharm InternationalDespite a long history of difficulties in this area, FDA once again is taking steps to facilitate the import of less costly prescription drugs from Canada by states, Indian Tribes, and other entities. The Canadian government has objected to the […]
May 19, 2022
Via: World Pharma NewsDrug shortages pose a significant public health threat as they can delay, and in some cases, even deny critically needed care for patients. Over the past decade, the FDA’s efforts have contributed to fewer new drug shortages and reduced the […]
May 16, 2022
Via: Drugs.comDealing with a crippling shortage of infant formula that has many U.S. parents desperate, the Food and Drug Administration on Monday announced ‘Increased flexibilities” in allowing foreign manufacturers to help boost American supply of the vital product. Also on Monday, […]
May 12, 2022
Via: Contract PharmaTaiwan-based contract development and manufacturing organization (CDMO) Bora Pharmaceuticals recently announced the establishment of Bora Biologics Co., Ltd., to focus on the development of bio-pharmaceuticals. Bora Biologics has investors Taishin Healthcare Limited Partnership and Dr. Allen Chao, founder of Tanvex […]
May 10, 2022
Via: Biopharma DiveOver the past few years, the Food and Drug Administration has come increasingly under scrutiny for its program to grant speedy approvals to drugs that show early signs of benefiting patients with life-threatening diseases. These so-called accelerated approvals have ushered […]
May 3, 2022
Via: FiercePharmaThe next China-developed immuno-oncology therapy to cross the FDA’s desk has been hit with bad news. Still, it will be half a year at least before Coherus BioScience and Junshi Bioscience get another crack at U.S. approval of their cancer […]
May 3, 2022
Via: FiercePharmaZosano Pharma’s headaches are intensifying. With the FDA again knocking back its transdermal migraine patch, the biotech has suspended its M207 program and made more layoffs to preserve its dwindling cash reserves. The patch uses microneedles to deliver zolmitriptan, a […]